AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06387706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified web-based pain management Program
Description: Gamified Program Development: The project aims to create a Gamified web-based pain management Program (GAP) tailored for older adults with chronic pain, enhancing engagement through gaming elements.~Inclusive Design Process: Older adults with chronic pain will actively participate in developing GAP, providing valuable feedback throughout the process.~Pilot Study Design: A pre and post study design will be employed, with a small pilot group of 4 participants to offer diverse perspectives in the program's development.~Educational Content \& Activities: GAP will feature interactive educational content on pain effects, medication, non-drug treatments, and exercises, delivered through a mobile-friendly web platform.
Study NCT02361554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept with SensSight Deep Brain Stimulation System
Description: Placement of Deep brain stimulation System for treatment of chronic auditory hallucinations in treatment-resistant schizophrenia
Study NCT05900089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
Study NCT06389292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisaftoclax (APG-2575)
Description: QD, oral administration, every 28 days for a dosing cycle.
Study NCT06389292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: QD, oral administration, every 28 days for a dosing cycle.
Study NCT06389292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: QD, hypodermic or intravenous injection, D1-7 in 28-day cycle.
Study NCT06389292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine Injection
Description: QD, hypodermic or intravenous injection, D1-7 in 28-day cycle.
Study NCT06077552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pyramidal training by treadmill
Description: pyramidal training by treadmill for 40 minutes per session three sessions per week for eight weeks in addition to the diet health advises
Study NCT05454046 — intervention group
Intervention type: OTHER
Intervention: Food intake among women and men in fertility treatment
Description: Filling in an FFQ
Study NCT06328244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple swallowing training
Description: Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week.
Study NCT06532604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroretinography (ERG)
Description: ERG are specifically carried out for research. They are performed in Nancy with the MonPackOne device developed by Metrovision for participants at center n°1, and in Paris with the RETeval device developed by LKS Technologie for participants at center n°2. Both devices comply with ISCEV standard and are CE marked. They enable the reccord of Pattern ERG, Flash ERG and Multifocal ERG using corneal and skin electrodes, or Sensor Strip skin electrodes only, for the Nancy and Paris centers respectively.
Study NCT06475885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Massage Program
Description: The experimental group received the International Association of Infant Massage (IAIM) Infant Massage Program starting from day 14 postpartum for a duration of 5 weeks.
Study NCT05836857 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cannabis (Marijuana)
Description: The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.
Study NCT05836857 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cannabidiol (CBD)
Description: The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education
Study NCT05428202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GN037
Description: GN-037 cream containing urea, salicylic acid, retinoic acid and clobetasol 17-propionate and matching placebo
Study NCT05428202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream containing base without active ingredients
Study NCT06366139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency thermocoagulation of the trigeminal ganglion
Description: The patient is placed in the supine position and the foramen ovale is identified medial to the coronoid process of the mandible by giving the head a submental oblique position under fluoroscopic guidance. A 20-gauge, 5 mm active type, and 100 mm radiofrequency cannula is inserted 2 cm lateral to the commissura labialis and advanced towards the foramen. After entering the foramen ovale with a lateral fluoroscopic image, the radiofrequency cannula is connected to the radiofrequency generator and sensory and motor stimulations are performed to confirm the target maxillary and mandibular nerves. The radiofrequency lesion is applied at 60°C, 65°C and 70°C for 60-seconds periods. The patient is observed for side effects for 1 hour after the procedure.
Study NCT06366139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary/Mandibular nerve pulsed radiofrequency
Description: The patient is placed in the lateral decubitus position with the affected side up. A 5-12 MHz linear ultrasound probe is placed in the infrazygomatic area above the maxilla at a 45° inclination in both the frontal and horizontal planes. The probe position allows visualization of the pterygopalatine fossa, which is limited to the maxilla anteriorly and the greater wing of the sphenoid posteriorly. Real-time ultrasound guidance allows direct localization of the internal maxillary artery and identification of the needle tip. The radiofrequency cannula was connected to the radiofrequency generator and PRF was applied at 42°C for 240 seconds after confirming the localization of the maxillary and mandibular nerve by obtaining appropriate responses to sensory and motor stimulation.
Study NCT06207240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroLife FES Sleeve / NeuroLife EMG-FES Sleeve
Description: Electrical stimulation will be delivered via the NeuroLife FES Sleeve and NeuroLife EMG-FES Sleeve devices to assist with movement during functional task practice.
Study NCT06302296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injectable form of PRF
Description: A group of patients in which participants will be undergo to orthodontic treatment will be received a 0.9 ml injection of PRF after 1st premolar extraction.
Study NCT06302296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: A group of patients in which participants will be undergo to traditional orthodontic treatment will be received a Placebo injection after 1st premolar extraction.
Study NCT05520970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19-1
Description: All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region
Study NCT05520970 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AdCLD-CoV19-1
Description: All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region
Study NCT04885894 — intervention group
Intervention type: DRUG
Intervention: Zeposia
Description: Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
Study NCT04416737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-rapid insulin
Description: Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
Study NCT06617351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Gummy - 7.5 kilocalories (kCal), 2 g Carbohydrate, 1.5 g total sugars, 7.5 mg sodium, 5 mg melatonin.
Study NCT06617351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gummy - 12.5 kilocalories (kCal), 3g Carbohydrate, 1.875 g total sugars, 1.25 mg sodium.
Study NCT06612463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine 6mg/kg
Description: In the caffeine trial, participants ingested a capsule containing 3 mg/kg caffeine 60 min prior to each rugby sevens match. There was 2 matches per day. So the total dosage is 6 mg/kg/ day
Study NCT06612463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo trial, participants ingested a capsule containing starch 60 min before each rugby sevens match. There were 2 matches per day
Study NCT06620315 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: RBM
Description: Resorbable Blast Media (RBM) implant surfaces can enhance osseointegration and implant stability
Study NCT06620315 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: sand blasted implant
Description: sand blasted implant
Study NCT06620913 — intervention group
Intervention type: OTHER
Intervention: Description of clinical, immunological and tumor features of patients harboring CV2 Abs
Description: This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.
Study NCT06618378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback exercise combined with breathing exercise
Description: Urotherapy training will be given at the beginning of the treatment process. Contraction and relaxation will be applied around the external sphincter in combination with diaphragmatic breathing by visual imagery with EMG biofeedback application. The second channel EMG will be placed on the transversus abdominus muscle and its activation will be checked. The treatment will be completed with 30-minute sessions twice a week for 12 weeks. Each session will consist of 40 cycles of 10 minutes of diaphragmatic breathing exercise followed by 20 minutes of 10 seconds of contraction followed by 20 seconds of relaxation.
Study NCT06618378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: urotherapy educational group
Description: 1. An important part of urotherapy is to provide parents and children with detailed explanations of etiology, prevalence and pathophysiology. This will reassure parents and help them understand the causes of the child's bedwetting accidents and the rationale for treatment. This will increase compliance with treatment.~2. Recommendations are given regarding appropriate fluid intake and regular voiding throughout the day. The child is encouraged to go to the toilet seven times a day and drink seven glasses of water.~3. The correct sitting position for the toilet is explained. If the feet do not touch the floor easily, it is recommended to use a step stool for foot support. Additionally, children are taught to relax their abdomen when peeing.~4. In addition to monitoring and motivation, a bladder diary should be kept to give the child and parents an idea about the progress of treatment, compliance with treatment and continuity.
Study NCT06618378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: urotherapy educational group
Description: 1. An important part of urotherapy is to provide parents and children with detailed explanations of etiology, prevalence and pathophysiology. This will reassure parents and help them understand the causes of the child's bedwetting accidents and the rationale for treatment. This will increase compliance with treatment.~2. Recommendations are given regarding appropriate fluid intake and regular voiding throughout the day. The child is encouraged to go to the toilet seven times a day and drink seven glasses of water.~3. The correct sitting position for the toilet is explained. If the feet do not touch the floor easily, it is recommended to use a step stool for foot support. Additionally, children are taught to relax their abdomen when peeing.~4. In addition to monitoring and motivation, a bladder diary should be kept to give the child and parents an idea about the progress of treatment, compliance with treatment and continuity.
Study NCT06618430 — intervention group
Intervention type: OTHER
Intervention: None (Observational Study)
Description: None (Observational Study)
Study NCT06624150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS sessions, StarStim device
Description: 10 active sessions of transcranial direct current stimulation paired with cognitive training tasks. Device used is StarStim.
Study NCT06624150 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (fake) tDCS sessions
Description: 10 fake sessions of transcranial direct current stimulation paired with cognitive training tasks. The device will be on the participants head, but the current will not be active.
Study NCT06622473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand dexterity assessement
Description: Each participant will perform the VET, with their most affected hand, followed by the VET with the less affected hand.
Study NCT06241261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride gel
Description: Application of 38% SDF gel every 6 months
Study NCT06241261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine fluoride solution
Description: Application of 38% SDF solution every 6 months
Study NCT06622265 — intervention group
Intervention type: DEVICE
Intervention: Electrocardiogram recording
Description: ECG recording with investigational device
Study NCT06624241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipo-Curcumin gel + SRP
Description: The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo- Curcumin gel. The pocket will be sealed with cyanoacrylate.
Study NCT06624241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lipo gel + SRP
Description: The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo gel. The pocket will be sealed with cyanoacrylate.
Study NCT06624241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discharged Gel + SRP
Description: The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of discharged gel. The pocket will be sealed with cyanoacrylate.
Study NCT06624241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP alone
Description: The pocket defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
Study NCT06623565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal image-guided resection
Description: Supramarginal resection using combination of ADC MRI and FET PET
Study NCT06628778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Dalteparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge
Study NCT04682652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene MicroSpheres
Description: Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
Study NCT05415371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care + Financial Incentives
Description: Financial incentive participants will receive standard care and receive incentives for completing counseling calls and for abstinence.
Study NCT05415371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
Study NCT05415371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
Study NCT05864053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be administered over a 45-minute period.
Study NCT05864053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (2R,6R)-hydroxynorketamine
Description: (2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.
Study NCT05864053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered over a 45-minute period.
Study NCT05119868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on Mediterranean Diet
Description: A personalized nutritional counseling and a tailored diet, according to Mediterranean dietary pattern, designed on the pre-pregnancy weight, height and trimester of pregnancy provided by certified dietitians.
Study NCT05519488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rubato Life Music
Description: Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
Study NCT05519488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music of their desire
Description: patients will be asked to listen to a minimum of 45 minutes per day of music (or a total of 12 hours), of their desire, which the participant considers as stress relief music for a period of a 2 weeks (or a total of 12 hours)
Study NCT05542797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duphastone
Description: dydrogesterone hormone
Study NCT06192992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral heating of 2 feet
Description: Heating of both feet
Study NCT06192992 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No heating
Study NCT05839106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1032 injection
Description: Subjects will receive PM1032 by intravenous administration.
Study NCT05097547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.
Study NCT06521255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitmab was infused intravenously
Study NCT06521255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally
Study NCT06521255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was infused intravenously
Study NCT06521255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was infused intravenously
Study NCT06521255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin was infused intravenously
Study NCT06521255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin was infused intravenously
Study NCT06521255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was infused intravenously.
Study NCT05334121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
Study NCT05334121 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product consumption
Description: Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.